Insights on Health Care
1139 total results. Page 30 of 46.
The Office of Inspector General for the Department of Health and Human Services recently published its Semiannual Report to Congress, for the period April 1 to September 30, 2018.
Arent Fox FDA Associate Emily Leongini will present at CBI’s Bio/Pharma Compliance Congress on Non-promotional Activities.
On November 30, HRSA announced that it is “notifying all stakeholders that the secure pricing component of the 340B Office of Pharmacy Affairs Information System (340B OPAIS) will be open for the submission of manufacturer pricing data in the first quarter of 2019.”
NEW YORK – Earlier this year, Yeshiva University’s Katz Graduate Business School introduced a new 36-credit Master of Science in Biotechnology Management and Entrepreneurship designed to prepare future business leaders in the life sciences to successfully navigate the launching new medical drugs.
The Centers for Medicare & Medicaid Services (CMS) released an advance notice of proposed rulemaking (the ANPR) seeking comments on its proposal to dramatically change the way the agency pays for separately payable Part B drugs and biologicals.
Headlines that Matter for Companies and Executives in Regulated Industries
Headlines that Matter for Companies and Executives in Regulated Industries
On October 26, 2018, the Health Resources and Services Administration (HRSA) updated its online National Practitioner Data Bank (NPDB) Guidebook for the first time since April 2015. The Guidebook provides information to eligible entities and professionals regarding reporting to the NPDB, querying th
As the dust settles on a campaign cycle that was unprecedented in many ways, we have composed this biennial post-election analysis to assist our clients in assessing the potential impact of the elections on their organizations and their industries.
Below is a roundup of headlines that matter and key takeaways from the industries and issues we’re following closely. We’ll be back later today with more in-depth analysis.
WASHINGTON — Twenty-four Arent Fox LLP practices have been recognized in the 2019 “Best Law Firms” rankings that are published annually by US News & World Report and Best Lawyers.
Headlines that Matter for Companies and Executives in Regulated Industries
The Department of Health and Human Services (HHS) has issued a proposed rule (PR) which would require any television advertisement for a drug or biological covered by Medicare or Medicaid to include a disclosure of the product’s “current list price” for a “typical” thirty day supply.
President Trump signed into law a bill that expands the Open Payments reporting requirements.
President Trump is expected to sign into law a bill which will – among other things – expand the scope of the Open Payments reporting requirements mandated by Section 6002 of the Patient Protection and Affordable Care Act (often referred to as the Sunshine Act).
Headlines that Matter for Companies and Executives in Regulated Industries
On September 28, 2018, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed an amended complaint to revive its lawsuit seeking to block implementation and enforcement of California’s drug price transparency law.
WASHINGTON — Arent Fox LLP is pleased to announce that Health Care Co-Leader Stephanie Trunk has been selected to the LMG Life Sciences Award List in the “Healthcare Pricing & Reimbursement” category.
Arent Fox is pleased to announce the launch of the Investigations Blog, a dedicated resource for legal updates and analysis on key enforcement news for companies and executives in highly regulated industries.
On September 11, 2018, hospital advocacy groups and three individual hospitals filed a complaint in the United States District Court for the District of Columbia.
A federal district court vacated in its entirety the Centers for Medicare and Medicaid Services’ (CMS) regulations regarding the reporting and returning of overpayments by Medicare Advantage plan insurers.
Health Care Partner Stephanie Trunk was interviewed by HealthLeader on a recent ruling that vacated the Medicare Advantage 2014 Overpayment Rule.
Health care plans are seeing an increase in the number of claims from their enrollees for reimbursement for mental health, behavioral, and substance abuse services obtained at “wilderness camps.”
On August 28, 2018, the United States District Court for the Eastern District of California (the Court) dismissed with leave to amend the Pharmaceutical Research and Manufacturers of America’s (PhRMA) lawsuit challenging the constitutionality of California’s new drug price transparency law.
The Department of Health and Human Services Office of the Inspector General published a request for information seeking public comments on what new or modified safe harbors to the Anti-Kickback Statute or exceptions to the beneficiary inducements prohibition.